Comments to FDA: Postmarketing Safety Reports for Human Drug and Biological Products Share page: Docket Number: FDA-2008-N-0334 Comments regarding a proposed rule on electronic submission requirements for postmarketing safety reports for human drug and biological products. Download Document Issues: OTC Medicines Related Posts Press Releases and Statements CHPA Applauds Bipartisan Bill to Streamline Access to Next-Generation Sunscreens in the U.S. Jun 4, 2025 Comments Comments Regarding Amending OTC Monograph M012: Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Human Use May 7, 2025 Letter Letter Regarding Office of Management & Budget Request for Information: Deregulation May 12, 2025